Vivani Medical, Inc.

NASDAQ:VANI

Medical - Devices

Healthcare
$1.05 +1.30%

+$0.02 today

Market cap
$94.71M
Beta
3.29
P/E (TTM)
-3.5
EPS (TTM)
-$0.33
52W Low $0.92High $1.92

Volume 0.18M

Average 0.24M

VANI Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Vivani Medical, Inc.NASDAQ: VANI

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $4.26M rose 1.0% year over year, behind the +11.9% change in trailing-twelve-month research & development. Sequentially, it fell 8.0% from the prior quarter. Over 3 fiscal years it compounded at +8.6% a year.

Context

  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +1.0% toward the trailing-twelve-month pace of +11.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.26M-8.0% QoQ
Last fiscal yearDec 2025
$18.13M+15.1% YoY
LTMMar 2026
$18.17M+11.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.0%——
1 year+15.1%——
3-year CAGR+8.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
18.13M USD
Year-over-year change
+15.1%
4-year CAGR
+13.3%

Research & Development vs competitors

How VANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +11.9% is the 4th highest of 8, against a peer median of -5.9%.
  • Over three fiscal years its annual growth of +8.6% compares with a peer median of -6.7%.
VANI Competitors
Research & Development for VANI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMAImageneBio IncLTM Mar 2026$30.77M USD+23.4%-23.7%—
RCELAVITA Medical, Inc.LTM Mar 2026$20.18M USD-5.9%+14.6%27.9%
VANIVivani Medical, Inc.LTM Mar 2026$18.17M USD+11.9%+8.6%—
HYPRHyperfine, Inc.LTM Mar 2026$16.26M USD-26.0%-14.7%106.1%
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$15.22M CAD+22.5%+0.1%—
MBOTMicrobot Medical Inc.LTM Mar 2026$6.11M USD-11.4%-6.7%5814.3%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$5.77M USD-21.5%-38.7%—
FONRFONAR CorporationLTM Mar 2026$1.77M USD+13.3%+1.8%1.7%
Peer median (excluding VANI) —-5.9%-6.7%67.0%

Competitors are the stored peer set for VANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00357K0424K
Gross Profit00(357K)0(424K)
Gross Margin—————
Research & Development11M14.17M16.97M15.75M18.13M
Selling, General & Admin2.32M5.37M10M8.93M9.43M
Operating Expenses13.32M21.24M26.61M24.68M27.13M
Depreciation & Amortization345K381K357K400K424K
EBITDA(12.43M)(19.16M)(25.3M)(23.09M)(26.19M)
EBITDA Margin—————
Operating Income(13.32M)(21.24M)(26.97M)(24.68M)(27.56M)
Operating Margin—————
Interest Income00000
Interest Expense00000
Other Income / Expenses550K7.35M1.31M1.19M947K
Income Before Tax(12.77M)(13.89M)(25.65M)(23.49M)(26.61M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(12.77M)(13.89M)(25.65M)(23.49M)(26.61M)
Net Margin—————
EPS (Basic)(0.33)(0.17)(0.50)(0.43)(0.43)
EPS (Diluted)(0.33)(0.17)(0.50)(0.43)(0.43)
Weighted Avg Shares36.25M38.24M50.85M54.98M62.39M
Weighted Avg Shares (Diluted)36.25M38.24M50.85M54.98M62.39M

Vivani Medical, Inc.

NASDAQ:VANI

Intrinsic Alpha fair value

Locked

Current Price

$1.05

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.